ea0041ep617 | Endocrine tumours and neoplasia | ECE2016
Broker Vanessa
, Freitag Helma
, Christen Friederike
, Briest Franziska
, Siegmund Britta
, Grabowski Patricia
Background: Pulmonary neuroendocrine neoplasms are heterogeneous in their clinical behavior and therapeutic options are still not satisfactory. The crosstalk of different signaling pathways in NEN cells appears to be more complex as known already. PKI-587 is a highly potent novel dual inhibitor of PI3K and mTORC1/C2.Aim: Therefore, we assessed the effects of PKI-587 in different pulmonary NEN cell lines compared to the established mTORC1 inhi...